The ‘Corporate Reputation of Pharma’ survey - the 2021 Asia edition is now in its 4th year, and two years into the Covid-19 pandemic). Between November 2021-February 2022, the survey collected the opinions of 300 Asian patient groups on the performance of the pharmaceutical industry during 2021 [see table below for the countries included in this Asia analysis].
Patient groups possess a unique understanding of the needs of patients, and represent their collated views. As such, patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. Many patient groups, too, are familiar with the complexities of pharma’s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve - all from a patient perspective.
The 300 Asian patient groups responding to the 2021 ‘Corporate Reputation of Pharma’ survey had, collectively, been in communication with nearly 2.7 million Asian patients during 2021. 70% of the respondent Asian patient groups worked or partnered with at least one pharma company that year.
The report provides details on:
- How the analyst measures pharma’s corporate reputation from a patient perspective;
- The headline results of the 2021 Asia element of the ‘Corporate Reputation’ survey; including specific results for Australasia and Japan;
- The companies included in the 2021 Asia analysis; and
- The profiles of 2021’s respondent Asian patient groups.
Companies assessed for corporate reputation in the 2021 Asia report
AbbVie - Amgen - Astellas Pharma - AstraZeneca - Bayer - Biogen - Boehringer Ingelheim - Bristol Myers Squibb - CSL Behring - Daiichi Sankyo - Eisai - Eli Lilly - Gilead Sciences - GSK - Ipsen - Janssen - LEO Pharma - Merck KGaA - MSD - Mylan - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche (known as Chugai in Japan) - Sandoz - Sanofi - Sun Pharma - Takeda - Teva - ViiV Healthcare
ASIA COMPANY RANKINGS IN 2021
- The top-three pharma companies in Asia in 2021, out of 31 companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups familiar with the company): Gilead Sciences, 1st - Pfizer, 2nd - ViiV Healthcare, 3rd.
- The top-three pharma companies in Asia in 2021, out of 18 companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups working/partnering with the company): Gilead Sciences, 1st - Pfizer, 2nd - Roche/Chugai, 3rd.
- The top-three ‘big-pharma’ companies in Asia in 2021, out of 13 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups familiar with the company): Pfizer, 1st - Roche/Chugai, 2nd - Novartis, 3rd.
- The top-three ‘big-pharma’ companies in Asia in 2021, out of 13 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups working/partnering with the company): Pfizer, 1st - Roche/Chugai, 2nd - GSK, 3rd.
Table of Contents
- Executive summary
- Relationships that Asian patient groups have with pharma, 2021
- Industry-wide findings in Asia, 2021
- Rankings of 31 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies
- Rankings of 18 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies
- Rankings of 13 ‘big-pharma’ companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies
- Rankings of 13 ‘big-pharma’ companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies
- Profiles of the 31 companies, 2021 (v. 2020)
Appendices
I. Profiles of respondent Asian patient groups, 2021
II. List of respondent Asian patient groups that wished to be attributed, 2021
III. Commentaries and feedback from respondent Asian patient groups on how pharma can improve, 2021-2022
IV. The corporate reputation of pharma, 2021 - Australasia edition [separate supplement]
V. The corporate reputation of pharma, 2021 - Japan edition [separate supplement]
Tables and Charts
- The ten indicators measuring corporate reputation, 2021
- The corporate reputation of the pharmaceutical industry in Asia over time, 2016-2021
- The corporate reputation of the pharmaceutical industry, 2021 v. 2020, in ten countries of Asia
- Percentage of respondent patient groups from ten countries in Asia on pharma’s effectiveness at supporting patients during the Covid-19 pandemic, 2021 Percentage of respondent Asian patient groups stating that pharma was “Excellent” or “Good” at innovation and at having high-quality products, 2016-2021
- Percentage of respondent patient groups from countries in Asia stating that pharma was “Excellent” or “Good” at innovation and at having high-quality products, 2021
- The 31 companies included in the 2021 ‘Corporate Reputation of Pharma’ Asia analyses
- Companies making the biggest rises in the Asia rankings, 2020 to 2021
- Respondent Asian patient groups, 2021: familiarity, and partnerships, with pharma companies
- The types of relationships that respondent Asian patient groups have with pharma companies, 2021
- The corporate reputation of the pharmaceutical industry in Asia, 2021 v. 2020 -compared with that of other healthcare sectors
- The corporate reputation of the pharmaceutical industry in Asia over time, 2016-2021
- How good or bad the pharmaceutical industry in Asia was in 2021 v. 2020 at carrying out specific activities important to Asian patients and patient groups
- Percentage of respondent Asian patient groups who thought the pharma industry was “Very effective” or “Effective” at supporting Asian patients during the Covid-19 pandemic, 2021 v. 2020
- How good or bad the pharmaceutical industry in Asia was over time at carrying out specific activities important to Asian patients and patient groups, 2014-2021
- Rankings of 31 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies
- Rankings of 18 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies
- Rankings of 13 ‘big-pharma’ companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies
- Rankings of 13 ‘big-pharma’ companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies
- Profiles of the 31 companies, 2021 (v. 2020)
Profiles of the 31 companies, 2021
- AbbVie
- Amgen
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol Myers Squibb
- CSL Behring
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Gilead Sciences
- GSK
- Ipsen
- Janssen
- LEO Pharma
- Merck KGaA
- MSD
- Mylan
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Roche (Chugai in Japan)
- Sandoz
- Sanofi
- Sun Pharma
- Takeda
- Teva
- ViiV Healthcare
Each company is profiled by the following measures:
- The number of respondent Asian patient groups familiar, and working, with the company, 2021.
- The profile of the respondent Asian patient groups familiar with the company (the number of patients reached; specialties; and geographic remit), 2021.
- The types of relationships that the company had with its respondent Asian patient-group partners, 2021.
- Company performance in Asia at the individual indicators of corporate reputation in 2021-as assessed by respondent Asian patient groups familiar, and working, with the company.
- Competitors’ relationships in 2021 with the company’s respondent Asian patient-group partners.
- Overall rankings in Asia for the company-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021 v. 2020.
- Company rankings in Asia for each of the indicators-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021 v. 2020.
- Snapshot view: where the company sits in the corporate tiers in Asia for each of the indicators (in the higher, the middle, or the lower tier)-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021.
- Overall rankings of the company in Asia, 2016-2021-expressed on the Patient Corporate Reputation Index (PCRI), a measure designed to standardise the analyst’s ranking data (preventing results from being skewed by the differing numbers of companies included in Asia’s historic analyses over the various years). PCRI ranking is from 0 to 1, with 1 being the best (the highest rank)-as assessed by respondent Asian patient groups familiar
Samples
LOADING...
Companies Mentioned
- AbbVie
- Amgen
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol Myers Squibb
- CSL Behring
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Gilead Sciences
- GSK
- Ipsen
- Janssen
- LEO Pharma
- Merck KGaA
- MSD
- Mylan
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Roche (Chugai in Japan)
- Sandoz
- Sanofi
- Sun Pharma
- Takeda
- Teva
- ViiV Healthcare
Methodology
LOADING...
